CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0144 (clinicaltrials.gov NCT No: NCT01363297)
Title:AN OPEN-LABEL, PHASE 1/2 STUDY OF INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOCYTIC LEUKEMIA
Principal Investigator:Hagop Kantarjian
Treatment Agent:Inotuzumab Ozogamicin
Study Status:Closed
Study Description:The goal of the first part of this clinical research study was to find the
highest tolerable dose of inotuzumab ozogamicin that can be given to patients
with ALL.

The goal of this part of the study is to learn if inotuzumab ozogamicin can
control the disease in patients with ALL. The safety of the drug will continue
to be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:Inotuzumab Ozogamicin
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Pfizer
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Hagop Kantarjian
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7026
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults